5-Methyl-2-propyloxazole | 53833-31-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-Methyl-2-propyloxazole
• 英文别名: 5-methyl-2-propyl-1,3-oxazole
• CAS: 53833-31-1
• 化学式: C₇H₁₁NO
• 分子量: 125.17
• InChiKey: NZRDFBNIWMSPHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
  申请人：Corkey Britton Kenneth

  公开号：US20120289493A1

  公开（公告）日：2012-11-15

  The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Q, R 1 , X 1 , X 2 , Y and R 2 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及一类为钠通道抑制剂的化合物，以及它们在治疗各种疾病状态中的应用，包括心血管疾病和糖尿病。在特定实施例中，该化合物的结构由式I给出： 其中Q、R1、X1、X2、Y和R2如本文所述，以及制备和使用该化合物的方法，以及含有该化合物的药物组合物。
• 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS
  申请人：Aicher Thomas D.

  公开号：US20090156603A1

  公开（公告）日：2009-06-18

  Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes meilitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

  提供了化学式I的化合物，这些化合物在治疗和/或预防由胰岛素活性不足引起的疾病中非常有用，例如糖尿病。还提供了治疗或预防由胰岛素活性不足或可以通过激活胰岛素来治疗的疾病和疾患的方法。
• THERAPEUTIC SUBSTITUTED PYRROLES
  申请人：Allergan, Inc.

  公开号：US20150336940A1

  公开（公告）日：2015-11-26

  Disclosed herein are compounds of the formula: compositions thereof, and methods for the treatment of glaucoma, reducing intraocular pressure, and other prostaglandin EP 2 mediated disease and disorders.

  本文披露了以下公式的化合物：其组合物以及治疗青光眼、降低眼内压和其他前列腺素EP2介导的疾病和紊乱的方法。
• GLUCOKINASE ACTIVATORS
  申请人：Aicher Thomas D.

  公开号：US20100056530A1

  公开（公告）日：2010-03-04

  Provided are compounds of Formula I wherein R 1 , R 2 , Y, Z and G are as defined herein, that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

  提供了式I化合物，其中R1、R2、Y、Z和G的定义如本文所述，这些化合物对于治疗和/或预防由胰岛素敏感性激酶活性不足引起的疾病（如糖尿病）是有用的。还提供了治疗或预防由胰岛素敏感性激酶活性不足或可以通过激活胰岛素敏感性激酶来治疗的疾病和疾病的方法。
• 3-substituted propionic acids as αV integrin inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10968219B2

  公开（公告）日：2021-04-06

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ay-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  本发明提供了式（I）化合物：或其立体异构体、同系物或药学上可接受的盐或溶液，其中所有变量如本文所定义。这些化合物是含αv整合素的拮抗剂。本发明还涉及包含这些化合物的药物组合物，以及通过使用这些化合物和药物组合物治疗与含ay整合素失调相关的疾病、紊乱或病症的方法，如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。